A study led by the London School of Hygiene & Tropical Medicine and the Vaccine Impact Modelling Consortium has found that countries with a relatively higher cervical cancer burden had relatively lower HPV vaccination coverage during 2010-22, and significant inequities in coverage were found within the Americas, Europe and Western Pacific Regions. Researchers used the PRIME (Papillomavirus Rapid Interface for Modelling and Economics) HPV vaccine impact model to estimate the lifetime health impact of HPV vaccination on cervical cancer burden in terms of deaths, cases, and disability-adjusted life years (DALYs) averted by vaccination in 84 countries. The health impact of HPV vaccination varied across the 84 countries and ranged from Switzerland to Tanzania at 2 to 34 deaths, 4 to 47 cases, and 40 to 735 DALYs averted per 1000 vaccinated adolescent girls over the lifetime of the vaccinated cohorts of 2010–22. The concentration index for the distribution of average coverage during 2010–22 among the 84 countries ranked by vaccine impact was 0.33 and highlights the wide inequities in HPV vaccination coverage.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.